Lars Fruergaard Jørgensen, Novo Nordisk CEO (Ludovic Marin/ Pool Photo via AP)
May 2, 2024 04:55 AM EDTUpdated 07:06 AM
Pharma

No­vo’s GLP-1 sales boost prof­its, yet full po­ten­tial still curbed by sup­ply squeeze

Ayisha Sharma

News Reporter

Anna Brown

News Reporter

No­vo Nordisk is still hit­ting a glass ceil­ing in rev­enues due to GLP-1 sup­ply con­straints even as sales keep ris­ing. The price of We­govy dropped …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times